Introduction {#Sec1}
============

Recent randomized controlled trials have demonstrated the mortality benefit of an implantable cardioverter-defibrillator (ICD) over optimal medical therapy in patients with left ventricular (LV) dysfunction \[[@CR1], [@CR2]\]. The Multicenter Automatic Defibrillator Implantation Trial (MADIT) II showed 31% reduction in relative risk of mortality among patients with prior myocardial infarction and a LV ejection fraction (LVEF) ≤30% \[[@CR1]\]. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) showed 23% reduction in relative risk of mortality in patients with LVEF ≤35% and New York Heart Association (NYHA) class II--III congestive heart failure due to ischemic or non-ischemic etiology \[[@CR2]\].

Despite the significant reduction in mortality shown in MADIT II and SCD-HeFT, the absolute benefits were relatively small: 5.6% over 20 months and 7.2% over 5 years, respectively \[[@CR1], [@CR2]\]. Because of concerns not only for the potential side effects of ICD \[[@CR3]--[@CR5]\] but also for the huge economic burden, further risk stratification to identify patients who are likely or unlikely to benefit from ICD seems to be necessary.

Microvolt-level T-wave alternans (TWA) in a body-surface electrocardiogram (ECG) was proposed as a non-invasive method to evaluate risk of sudden cardiac death (SCD) or lethal ventricular tachyarrhythmia \[[@CR6]\]. Although high negative predictive values of TWA have been reported \[[@CR6]--[@CR11]\], recent studies have reported conflicting data on the prognostic value of TWA \[[@CR12]--[@CR14]\]. Furthermore, TWA cannot be assessed in patients with persistent atrial fibrillation (AF), ventricular pacing or exercise intolerance, who account for a sizable portion of the entire population of patients with LV dysfunction \[[@CR15]--[@CR17]\].

To address these issues, we have conducted a multicenter, prospective study assessing the predictive value of TWA for SCD or lethal ventricular tachyarrhythmia in a broad population of Japanese patients with LV dysfunction, including those ineligible for the TWA test.

Methods {#Sec2}
=======

Study design and patient enrollment {#Sec3}
-----------------------------------

The Prospective Evaluation of Ventricular Tachyarrhythmic Events and Sudden Cardiac Death in Patients with Left Ventricular Dysfunction (PREVENT-SCD) study is a prospective multicenter registry of Japanese patients with LV dysfunction, designed to evaluate the prognostic value of TWA and other potential arrhythmia risk factors for ventricular tachyarrhythmia. The study design is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study design of the PREVENT-SCD study

Patients with LVEF ≤40% without treatable cardiac ischemia, who had NYHA class I--III heart failure, were eligible for the study. All patients had to be maintained on an optimal dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers before enrollment in the study unless these drugs were contraindicated or patients were intolerant.

Patients were excluded if they had a history of sustained ventricular fibrillation (VF) or ventricular tachycardia (VT), had previous ICD implantation, had NYHA class IV heart failure, had a myocardial infarction (MI) within the past month, had undergone coronary revascularization within the past 3 months, had treatable cardiac ischemia, had scheduled coronary revascularization or cardiac surgery, or had any condition other than cardiac disease with expectation of survival less than 1 year.

LV function was assessed by echocardiography using modified Simpson's method. When echocardiography was considered inappropriate due to poor images, then magnetic resonance imaging, angiography or radionuclide scanning was used to assess LV function.

Ischemic cardiomyopathies were defined as LV dysfunction associated with a documented history of MI or severe narrowing of at least one of the three major coronary arteries. The others were classified as non-ischemic cardiomyopathies. Absence of treatable cardiac ischemia was confirmed by a stress test and/or coronary angiography.

Between June 2004 and February 2007, a total of 453 patients were enrolled from 38 centers in Japan ([Appendix 1](#Sec13){ref-type="sec"}). Patients were scheduled to undergo TWA and other risk stratification tests, including 12-lead ECG and Holter ECG as mandatory tests and signal-averaged ECG and electrophysiological (EP) study as optional tests. Therapeutic strategies based on the results of the risk stratification tests were determined within 2 months of enrollment. The choice of therapeutic strategy, such as ICD implantation, was left to the discretion of the attending physicians. Device programming in ICD patients was not prespecified in this study. Case-specific programming was made at individual centers.

The relevant review boards or ethics committees in all participating centers approved the research protocol. Written informed consent was obtained from all patients.

Risk stratification tests {#Sec4}
-------------------------

The TWA test was performed in all eligible patients. Patients underwent the TWA test while taking their regular medication, including beta-blockers. Careful skin preparation was performed and high-resolution electrodes were used to minimize noise. ECG leads were placed at the standard 12-lead positions and in an orthogonal X, Y and Z configuration. Measurements were made with a CH2000 or Heartwave system (Cambridge Heart Inc., Bedford, MA, USA). The result of the TWA test was automatically interpreted by the Alternans Report Classifier within the CH2000 or Heartwave system, reviewed by EP cardiologists at each individual center, and classified into positive, negative or indeterminate according to previously described criteria \[[@CR18]\].

Because patients with indeterminate and positive TWA tests have been reported to have a similar arrhythmic or mortality risk \[[@CR19]\], they were prospectively combined for analysis as 'non-negative' TWA tests. In this study, therefore, comparisons were made among patients with negative TWA, patients with non-negative (positive or indeterminate) TWA, and those ineligible for the TWA test.

Resting 12-lead ECG was evaluated for basic cardiac rhythm, heart rate, QRS duration, and QRS morphology. Holter ECG was evaluated for number of premature ventricular contractions (PVCs), as well as the presence or absence of non-sustained VT (NSVT). NSVT was defined as 3-30 PVCs at a rate \>100/min.

Other potential arrhythmia risk predictors included age, sex, etiology of LV dysfunction, NYHA class, diabetes, hypertension, hyperlipidemia, AF, ventricular pacing, blood pressure, LVEF, LV end-diastolic dimension (LVEDD), mitral regurgitation, renal failure, anemia, brain natriuretic peptide (BNP) level and medication at the time of enrollment.

Follow-up and end points {#Sec5}
------------------------

All patients were followed in each participating center at least yearly after enrollment, either by hospital visits or telephone contact with the patients. When clinical events were suspected by telephone interview with the patients, they were confirmed by contact with the referring physicians. All ICD patients were followed at least every 6 months by hospital visits, and all ICD data were obtained by interrogation of the device. Clinical data were prospectively collected according to pre-specified definitions.

The prespecified primary end point of the study was a severe ventricular tachyarrhythmic event (SVTE), defined as a composite of SCD, sustained rapid-VT (≥188/min) or VF, and appropriate ICD therapy for rapid-VT (≥188/min) or VF. The secondary end points were all-cause death, cardiac death, and a ventricular tachyarrhythmic event (VTE) defined as a composite of SVTE, sustained VT (\<188/min) and appropriate ICD therapy for VT (\<188/min). SCD was defined as unexpected natural death occurring instantaneously or within 24 h of the onset of acute symptoms or signs, of which the cause was proved to be cardiac at necropsy or assumed to be cardiac because of clinical circumstances. Unwitnessed death of unknown cause was also regarded as SCD.

All of the primary and secondary events were adjudicated by a clinical events committee ([Appendix 2](#Sec14){ref-type="sec"}).

Statistical analyses {#Sec6}
--------------------

All continuous variables are expressed as mean ± SD or median. Statistical significance between the groups was assessed by Student's *t* test for parametrically distributed continuous variables, the Wilcoxon rank sum test for non-parametrically distributed continuous variables, and Pearson's *χ*^2^ test for categorical variables.

Event-free survival was calculated by the Kaplan--Meier method. The significance of differences in event-free survival between groups was assessed with a log-rank test. Cox proportional hazards models were used to identify independent predictors of SVTE. Two dummy variables were created to reflect three levels of TWA status in the cohort: a negative test, a non-negative (positive or indeterminate) test, and no test (ineligible for the TWA test). The continuous variables were dichotomized by clinically meaningful reference values or median values. We first selected variables with *P* values \<0.1 in the univariable Cox models and then included them simultaneously in the multivariable models. Patients with missing values for any selected variable were excluded from the multivariable analysis. The independent predictors of SVTE were identified by the forward and backward stepwise methods with inclusion and exclusion *P* values \<0.05. Relative risks are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All tests were 2-sided, and a *P* value \<0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

The clinical characteristics of the 453 patients enrolled in the PREVENT-SCD study are listed in Table [1](#Tab1){ref-type="table"}. The average age was 65.1 ± 12.6 years, and 367 (81%) were male. The etiology was ischemic in 189 (42%) and non-ischemic in 264 (58%). The mean LVEF was 29.2 ± 7.4%. Among the 189 ischemic patients, 170 (90%) had had prior coronary revascularization.Table 1Patient characteristicsBaseline characteristics Age65.1 ± 12.6 Male367 (81%) NYHA-III128 (28%) Ischemic189 (42%) Non-ischemic264 (58%)Risk factors and co-morbidities Prior MI180 (40%) CABG/PCI170 (38%) Stroke or TIA41 (9%) Diabetes125 (28%) Hypertension207 (46%) Hyperlipidemia144 (32%) AF120 (26%) Persistent AF65 (14%) Pacemaker56 (12%) Systolic BP (mmHg)119 ± 22 Systolic BP \<100 mmHg74 (16%) Diastolic BP (mmHg)69 ± 12 Hemoglobin \<12 g/dL108 (24%) eGFR \<40 mL/min/1.73 m^2^90 (20%) BNP (pg/mL)211 BNP ≥200 pg/mL228 (52%)Echocardiography LVEF (%)^a^29.2 ± 7.4 LVEF ≤30%228 (50%) LVEDD (mm)62.3 ± 8.9 LVEDD ≥70 mm90 (20%) MR grade 3 or 458 (13%)Medications ACEIs or ARBs375 (83%) Beta-blockers331 (73%) Diuretics350 (77%) Spironolactone236 (52%) Digitalis139 (31%) Amiodarone81 (18%) Aspirin229 (51%) Statin131 (29%)Risk stratification tests TWA (*N* = 280)  Negative82 (29%)  Positive138 (49%)  Indeterminate60 (21%)Resting 12-lead electrocardiogram (*N* = 453) Heart rate (/min)71 QRS (ms)113 QRS ≥120 ms199 (44%)Holter monitoring (*N* = 433) PVC \>10/h231 (53%) NSVT157 (36%)Antiarrhythmic therapies ICD111 (25%) ICD with CRT46 (10%)*ACEIs* angiotensin-converting enzyme inhibitors, *AF* atrial fibrillation, *ARBs* angiotensin receptor blockers, *BNP* brain natriuretic peptide, *BP* blood pressure, *CABG* coronary artery bypass grafting, *CRT* cardiac resynchronization therapy, *eGFR* estimated glomerular filtration rate, *ICD* implantable cardioverter-defibrillator, *LVEDD* left ventricular end-diastolic dimension, *LVEF* left ventricular ejection fraction, *MI* myocardial infarction, *MR* mitral regurgitation, *NSVT* non-sustained ventricular tachycardia, *NYHA* New York Heart Association, *PCI* percutaneous coronary intervention, *PVC* premature ventricular contraction, *TIA* transient ischemic attack, *TWA* T-wave alternans^a^Measured by modified Simpson's method. For 33 patients with poor echo images, magnetic resonance imaging was used in 15 patients, angiography in 15 patients, and radionuclide scanning in 3 patients

TWA could be evaluated in 280 patients (62%), and the results were negative in 82 (29%), positive in 138 (49%), and indeterminate in 60 (21%). The TWA test was performed by an exercise test in 251 patients (90%) and by atrial pacing in 29 (10%). The reason for ineligibility for the TWA test was presence of AF in 65 patients (38%), presence of ventricular pacing in 34 (20%), presence of both AF and ventricular pacing in 12 (7%), exercise intolerance in 50 (29%), and other causes in 12 (7%). The reason for the indeterminate TWA results was an inadequate heart rate increase in 29 patients (48%), frequent ectopies in 13 (22%), excessive noise in 10 (17%), and other causes in 8 (13%).

Resting 12-lead ECG was available in all patients. Forty-four percent of patients had QRS duration ≥120 ms. Holter monitoring was performed in 433 patients (95%). PVC \>10/h and NSVT were documented in 53 and 36%, respectively.

ICD was implanted in 111 patients (25%), 46 of which were in combination with cardiac resynchronization therapy.

Table [2](#Tab2){ref-type="table"} shows comparison of patients according to TWA status. TWA-non-negative patients had a higher prevalence of frequent PVCs than TWA-negative patients. Those ineligible for the TWA test were older, were associated with more severe heart failure symptoms, had higher BNP levels, had a wider QRS duration, and had a higher prevalence of AF or digitalis use as compared with TWA-negative patients. An ICD was used more often in TWA non-negative patients than in TWA-negative patients.Table 2Comparison of patients according to TWA statusTWA-negative (*N* = 82)TWA-non-negative (*N* = 198)Ineligible for TWA (*N* = 173)Age60.5 ± 15.463.8 ± 12.368.7 ± 10.2^†^Ischemic41 (50%)94 (57%)54 (31%)^†^NYHA-III13 (16%)34 (17%)81 (47%)^†^AF6 (7%)21 (11%)93 (54%)^†^Systolic BP (mmHg)120 ± 23120 ± 20117 ± 23Hemoglobin (g/dL)13.6 ± 1.813.4 ± 3.213.3 ± 2.2BNP (pg/mL)155174286^†^LVEF (%)29.8 ± 7.229.2 ± 7.228.8 ± 7.6LVEDD (mm)61.2 ± 8.063.2 ± 8.961.7 ± 9.2MR grade 3 or 48 (10%)23 (12%)27 (16%)Digitalis21 (26%)41 (21%)77 (45%)QRS (ms)103109127^†^PVC \>10/h31 (39%)105 (54%)\*95 (60%)^†^NSVT25 (31%)66 (34%)66 (42%)ICD12 (15%)60 (30%)\*39 (23%)Abbreviations as in Table [1](#Tab1){ref-type="table"}\* *P* \< 0.05; ^†^ *P* \< 0.005 in comparison with TWA-negative group

Long-term clinical outcome {#Sec9}
--------------------------

During the median follow-up of 36 months (interquartile range 27--41 months), there were 47 first SVTEs, 70 first VTEs, and 68 deaths including 44 cardiac deaths (Table [3](#Tab3){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} shows the event-free curves for the primary end point of SVTE according to TWA status. The event-free rate for SVTE in TWA-negative patients was high, 100% at 1 year, 98.6% at 2 years, and 97.0% at 3 years. Both TWA-non-negative patients and those ineligible for the TWA test had significantly worse 3-year event-free rates for SVTE as compared with TWA-negative patients (89.5% with *P* = 0.037 and 84.4% with *P* = 0.003, respectively). When TWA-non-negative patients were separated into TWA-indeterminate and TWA-positive patients, the corresponding 3-year event-free rate for SVTE was 92.5% (*P* = 0.22) and 88.1% (*P* = 0.02), respectively. Among patients ineligible for the TWA test, those with AF, ventricular pacing or exercise intolerance had similar 3-year event-free rates for SVTE (81.2, 85.7, and 86.5%, respectively; *P* = 0.72).Table 3Primary and secondary end points during follow-upFirst SVTE47 (10.4%) SCD15^a^ Sustained rapid-VT/VF (≥188/min)8 ICD therapy for rapid-VT/VF (≥188/min)24First VTE70 (15.5%) SVTE31^b^ Sustained VT (\<188/min)3 ICD therapy for VT (\<188/min)36Death68 (15.0%) Cardiac death44 (9.7%) SCD17 (3.8%)*SCD* sudden cardiac death, *SVTE* severe ventricular tachyarrhythmic event, *VF* ventricular fibrillation, *VT* ventricular tachycardia, *VTE* ventricular tachyarrhythmic event^a^Out of 17 SCDs, 15 were first SVTE^b^Out of 47 SVTEs, 31 were first VTEFig. 2Event-free curves for the primary end point of SVTE according to TWA status

Univariable and multivariable predictors of the primary end point are shown in Table [4](#Tab4){ref-type="table"}. Multivariable analysis identified both non-negative TWA (HR 4.43; 95% CI 1.02--19.2; *P* = 0.047) and ineligibility for the TWA test (HR 6.89; 95% CI 1.59--29.9; *P* = 0.010) to be independent predictors of SVTE. When non-negative TWA was separated into indeterminate and positive TWA, the corresponding adjusted HR for indeterminate and positive TWA was 2.67 (95% CI 0.48--14.7; *P* = 0.26) and 5.36 (95% CI 1.22--23.7; *P* = 0.027), respectively. There was no significant interaction between TWA status and other clinical variables, including age, etiology of LV dysfunction, LVEF and QRS duration (Table [5](#Tab5){ref-type="table"}).Table 4Univariable and multivariable predictors of SVTEVariablesUnivariable analysisMultivariable analysisUnadjusted HR (95% CI)*P* valueAdjusted HR (95% CI)*P* valueTWA Ineligible6.69 (1.59--28.2)0.0106.89 (1.59--29.9)0.010 Non-negative4.15 (0.97--17.8)0.0564.43 (1.02--19.2)0.047MR grade 3 or 44.69 (2.56--8.61)\<0.0013.61 (1.80--7.27)\<0.001Age \<65 years1.70 (0.95--3.02)0.0722.48 (1.32--4.68)0.005Systolic BP \<100 mmHg2.91 (1.58--5.38)0.0012.43 (1.25--4.73)0.009PVC \>10/h3.01 (1.52--5.95)0.0022.35 (1.16--4.76)0.017NSVT2.56 (1.41--4.64)0.002----LVEDD ≥70 mm2.22 (1.21--4.06)0.010----BNP ≥200 pg/mL2.13 (1.14--3.96)0.017----QRS ≥120 ms1.91 (1.07--3.40)0.029----AF1.87 (1.04--3.37)0.037----Digitalis1.78 (1.00--3.16)0.050----LVEF ≤35%2.12 (0.90--4.96)0.060----Hemoglobin \<12 g/dL1.75 (0.95--3.23)0.087----*CI* confidence interval, *HR* hazard ratio. Other abbreviations as in Table [1](#Tab1){ref-type="table"}Table 5Risk of SVTE according to TWA status in patient subgroupsSubgroupsEvents/*n* (%)Hazard ratio (95% CI)Interaction *P*\*Age0.09/0.20 \<65 years  TWA-negative1/46 (2.2%)  TWA-non-negative13/91 (14.3%)7.69 (1.01--58.8)  Ineligible for TWA12/58 (20.7%)11.21 (1.46--86.2) ≥65 years  TWA-negative1/36 (2.8%)  TWA-non-negative6/107 (5.6%)1.92 (0.23--16.0)  Ineligible for TWA14/115 (12.2%)4.44 (0.58--33.8)Etiology of LV dysfunction0.19/0.10 Ischemic  TWA-negative2/41 (4.9%)  TWA-non-negative8/94 (8.5%)1.87 (0.40--8.79)  Ineligible for TWA6/54 (11.1%)2.38 (0.48--11.8) Non-ischemic  TWA-negative0/41 (0%)  TWA-non-negative11/104 (10.6%)--^a^  Ineligible for TWA20/119 (16.8%)--^a^LVEF0.19/0.05 ≤35%  TWA-negative1/63 (1.6%)  TWA-non-negative17/160 (10.6%)7.06 (0.94--53.09)  Ineligible for TWA23/130 (17.7%)12.52 (1.69--92.74) \>35%  TWA-negative1/19 (5.3%)  TWA-non-negative2/38 (5.3%)1.06 (0.14--12.51)  Ineligible for TWA3/43 (7.0%)1.30 (0.10--11.71)QRS duration0.46/0.05 ≥120 ms  TWA-negative0/24 (0%)  TWA-non-negative7/72 (9.7%)--^a^  Ineligible for TWA20/103 (19.6%)--^a^ \<120 ms  TWA-negative2/58 (3.4%)  TWA-non-negative12/126 (9.5%)2.91 (0.51--12.6)  Ineligible for TWA6/70 (8.6%)2.51 (0.65--13.0)\* *P* for interaction between TWA and each variable based on difference in probabilities of events; TWA-negative versus TWA-non-negative (left) and TWA-negative versus ineligible for TWA (right)^a^Indeterminate because of no events in TWA-negative group

Event-free curves for the secondary end points are shown in Fig. [3](#Fig3){ref-type="fig"}. Those ineligible for the TWA test had significantly worse event-free rates for all secondary end points as compared with TWA-negative patients with a HR of 3.15 for VTE (95% CI 1.33--7.47), 3.57 for all-cause death (95% CI 1.40--9.11), and 12.5 for cardiac death (95% CI 1.69--91.9). TWA-non-negative patients had significantly worse cardiac survival than TWA-negative patients (HR 7.71; 95% CI 1.04--57.7).Fig. 3Event-free curves for the secondary end points according to TWA status. Event-free curves for VTE (**a**), all-cause death (**b**) and cardiac death (**c**)

TWA negative patients had higher 3-year event-free rate for a composite of all-cause death and SVTE (91.9%) as compared with TWA-non-negative patients (81.7%, *P* = 0.03) and those ineligible for the TWA test (74.5%, *P* = 0.0004). The 3-year event-free rate for cardiac death or SVTE was 97.0, 86.2 (*P* = 0.008), and 78.9% (*P* \< 0.0001), respectively.

Discussion {#Sec10}
==========

The present study focused on the predictive value of TWA for lethal ventricular tachyarrhythmia in a broad population of patients with LV dysfunction. The event-free rate for SVTE in TWA-negative patients was excellent, 100% at 1 year, 98.6% at 2 years, and 97.0% at 3 years, which may suggest that TWA-negative patients can be safely excluded as ICD candidates. When those ineligible for the TWA test were taken into account, however, the TWA-negative patients accounted for only 18% of the entire study population. Thus, despite the strikingly high negative predictive value of TWA for SVTE, the safety assurance afforded by a negative result of the TWA test was applicable to only a limited proportion of patients with LV dysfunction.

The other important finding of this study was the poor long-term prognosis of patients ineligible for the TWA test. Ineligibility for the TWA test was associated with highest risk not only for the primary end point of SVTE but for all of the secondary end points, including VTE, all-cause death and cardiac death.

All previous TWA studies have excluded patients ineligible for the TWA test. Exclusion of those patients might be associated with considerable selection bias toward patients with good exercise capacity and those without AF or ventricular pacing. Although the prevalence of negative TWA among eligible patients with LV dysfunction has been reported to be 22--37% \[[@CR8]--[@CR14]\], a value coincident with the 29% observed in the present study, the proportion of TWA-negative patients among all patients with LV dysfunction has not previously been established. In addition, the long-term arrhythmia and mortality risk of patients ineligible for the TWA test has been uncertain. To the best of our knowledge, our study is the first multicenter study evaluating the prognostic utility of TWA in a real-world population of LV dysfunction patients, including those ineligible for the TWA test. TWA showed high negative predictive ability for lethal ventricular tachyarrhythmia and cardiac mortality, but the proportion of TWA-negative patients was less than one-fifth of the entire study population. Those ineligible for the TWA test had highest arrhythmia and mortality risk.

To date, seven multicenter studies assessing the predictive value of TWA for lethal ventricular tachyarrhythmia in patients with LV dysfunction have been reported (Supplementary Table) \[[@CR8]--[@CR14]\]. Four of those studies reported the significant prognostic utility of TWA with high negative predictive values for arrhythmic events \[[@CR8]--[@CR11]\], as shown in our study. However, the other three more recent studies have reported conflicting data on the predictive value of TWA \[[@CR12]--[@CR14]\]. The Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients (MASTER) trial and the SCD-HeFT substudy showed no difference in arrhythmic event rates between TWA-negative and TWA-non-negative patients \[[@CR12], [@CR13]\]. Furthermore, in the Alternans Before Cardioverter Defibrillator (ABCD) trial, TWA showed limited predictive ability for lethal ventricular tachyarrhythmia. The difference in the primary event rates between TWA-negative and TWA-non-negative patients was significant up to 9 months, but no longer after 12 months \[[@CR14]\].

There are several possible explanations for these conflicting results. First, among the studies there were substantial differences in TWA protocol, which might have influenced the predictive accuracy of the TWA test. In four studies including MASTER, SCD-HeFT and ABCD, beta-blockers were withheld for ≥24 h before the TWA test in order to reduce indeterminate TWA results due to an inadequate heart rate increase during exercise. However, Klingenheben et al. \[[@CR20]\] reported that metoprolol and sotalol decreased TWA amplitude by 35 and 38%, respectively. Also, in a study by Rashba et al. \[[@CR21]\], intravenous beta-blocker of esmolol reduced the number of positive TWA tests by 50%. These data suggest that beta-blockers should be continued at the time of the TWA test. In a recent meta-analysis of TWA studies by Chan et al. \[[@CR22]\], non-negative TWA was associated with a fivefold increased risk for ventricular tachyarrhythmia as compared with negative TWA in studies where beta-blockers were continued during the TWA test, while only a much weaker association was observed in studies where beta-blockers were withheld prior to the TWA test.

Second, it may be that previous studies did not exclude patients with treatable cardiac ischemia, which could affect the prognostic value of the TWA test. Patients with heavy ischemic burden are considered to have higher risk for a future coronary event, which is often associated with lethal ventricular tachyarrhythmia in patients with LV dysfunction \[[@CR23]\]. In the present study, coronary artery disease was well treated among ischemic patients, none of whom had treatable cardiac ischemia.

Third, the prevalence of ICD use was much higher in MASTER and ABCD, 100 and 87%, respectively, as compared with 25% in the present study. The use of appropriate ICD therapy for ventricular tachyarrhythmia as a surrogate end point for SCD may overestimate arrhythmic events, by counting potential self-terminating tachycardia as events \[[@CR24]\]. Thus, a higher prevalence of ICD use may lead to a higher possibility of overestimating arrhythmic events.

The low prevalence of ICD use in the present study was largely due to the fact that reimbursement officially covers ICDs only for secondary prevention of SCD in Japan. Because patient enrollment of this study started in June 2004, when the results of MADIT II and SCD-HeFT had been already published or announced, therapeutic strategies (i.e., whether to implant ICD or not) were left to the discretion of the attending physician. As a result, ICD patients were much sicker than Non-ICD patients in terms of lower systolic blood pressure, higher BNP level, lower LVEF, larger LVEDD, wider QRS duration, lower prevalence of negative-TWA, and higher prevalence of moderate to severe mitral regurgitation, PVC \>10/h, or NSVT (data not shown).

The TWA test was initially developed as risk stratification test for lethal ventricular tachyarrhythmia mainly in ischemic patients \[[@CR6]--[@CR8]\], but recent studies indicate that predictive values of TWA might be higher in non-ischemic patients than in ischemic patients \[[@CR9], [@CR13]\]. Consistently, in the present study, the negative predictive value of TWA for SVTE was 100% in non-ischemic patients, as compared with 95.1% in ischemic patients, although the difference was not statistically significant (Table [5](#Tab5){ref-type="table"}).

Because follow-up duration of previous studies reporting high predictive values of TWA ranged from 17 to 20 months \[[@CR6]--[@CR11]\], it has been uncertain whether the prognostic utility of TWA remains robust beyond 2 years. In the present study, the median of follow-up was 36 months, which was the longest among the multicenter TWA studies. The 3-year event-free rates for SVTE and cardiac death in TWA-negative patients were extremely high, 97.0 and 98.6%, respectively. Our data suggest that the predictive value of TWA remains robust over 3 years.

Limitations {#Sec11}
===========

The present study has several important limitations. First, the number of patients enrolled in this study was not large enough, considering the broad spectrum of its patient population. Second, the number of patients screened and excluded in this study was not recorded. Considering the relatively slow rate of patient enrolment, there may be some selection bias in our study population. Third, inclusion of appropriate ICD therapy in the composite primary end point may overestimate arrhythmic events, as discussed above. However, the prevalence of ICD use in the present study was relatively low as compared with other recent studies. Fourth, the rate of self-terminating ventricular tachycardia in patients without an ICD could not be determined. Fifth, device programming in ICD patients was not prespecified in this study. All intra-cardiac ECGs of ICD therapies were, however, reviewed by the clinical events committee. Finally, the results of the TWA test were determined at each participating center without a core laboratory so that the data would more closely represent general clinical practice. Conversely, there may be some heterogeneity in the interpretation of the TWA test results.

Conclusions {#Sec12}
===========

The present study demonstrated high negative predictive ability of TWA for lethal ventricular tachyarrhythmia in a real-world Japanese population of LV dysfunction patients during the median follow-up of 3 years. However, the TWA-negative patients accounted for only 18% of the entire population, including those ineligible for the TWA test. Thus, despite the strikingly high negative predictive value of TWA for lethal ventricular arrhythmia, the safety assurance given by a negative result of the TWA test was applicable to only a limited proportion of patients with LV dysfunction.

Those ineligible for the TWA test were associated with highest risk for lethal ventricular tachyarrhythmia, as well as highest overall and cardiac mortality.

Our study warrants further investigation with a larger patient population and a longer follow-up period.
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The following centers and investigators participated in the PREVENT-SCD study (listed in alphabetical order according to center):

Ehime Prefectural Central Hospital: Yukio Kazatani, Shinichi Hiramatsu, Tsuyoshi Matsunaka, Sumiko Sato; Fujita Health University Hospital: Hitoshi Hishida, Eiichi Watanabe; Funabashi Municipal Medical Center: Shun Ozawa, Masayuki Inagaki; Himeji Cardiovascular Center: Teishi Kajiya, Kohei Yamashiro, Katsunori Okajima; Hirosaki University School of Medicine & Hospital: Ken Okumura, Atsushi Iwasa, Masaomi Kimura, Hyogo Prefectural Amagasaki Hospital: Yoshiki Takatsu, Ryoji Taniguchi; International Medical Center of Japan: Mitsuo Kashida, Osamu Okazaki; Kagoshima University Medical And Dental Hospital: Chuwa Tei, Shuichi Hamasaki, Kobe University Hospital: Mitsuhiro Yokoyama, Akihiro Yoshida; Kokura Memorial Hospital: Masakiyo Nobuyoshi, Kenji Ando, Hitoshi Okabayashi, Jyota Nakano; Kurashiki Central Hospital: Kazuaki Mitsudo Satoki Fujii; Kurume University Hospital: Teruhisa Yoshida, Yasutsugu Nagamoto, Eiichi Takii; Kyorin University Hospial: Hideaki Yoshino, Takanori Ikeda; Kyoto University Graduate School of Medicine: Takeshi Kimura, Satoshi Shizuta, Yoshisumi Haruna, Takahiro Doi, Yukiko Nishio, Neiko Ozasa, Kei Nishiyama, Toru Kita, Takeshi Morimoto; Kyoto-Katsura Hospital: Shigeru Nakamura, Yoshihisa Enjoji; Mitsubishi Kyoto Hospital: Shinji Miki, Yutaka Kono; Nagoya University Hospital: Toyoaki Murohara, Yasuya Inden; National Defense Medical College Hospital: Fumitaka Ohsuzu, Koh Arakawa; Niigata University Medical & Dental Hospital: Yoshifusa Aizawa, Hiroshi Furushima; Nippon Medical School Hospital: Takao Kato, Yoshinori Kobayashi; Oita University Hospital: Tetsunori Saikawa, Naohiko Takahashi; Okayama University Hospital: Tohru Ohe, Satoshi Nagase; Ome Municipal General Hospital: Kenichiro Otomo; Sakurabashi Watanabe Hospital: Hiroshi Ito, Koichi Inoue; Shiga University of Medical Science Hospital: Minoru Horie, Takashi Yamamoto, Masanori Fujii, Makoto Ito; Showa University Fujigaoka Hospital: Youichi Takeyama, Yukei Higashi; St. Marianna University School of Medicine Hospital: Fumihiko Miyake, Ryouji Kishi, Kiyoshi Nakazawa; St. Marianna University School of Medicine, Yokohama City Seibu Hospital: Haruki Musha, Osamu Miyatsu; Teikyo University Hospital: Takaaki Isshiki, Taiji Furukawa; Teikyo University School of Medicine University Hospital, Mizonokuchi: Tomoyuki Kunishima; The Hospital of Hyogo College of Medicine: Mitsumasa Ohyanagi, Hiroki Shimizu; Toho University Ohashi Medical Center: Kaoru Sugi, Takao Sakata; Tokyo Medical and Dental University Hospital Faculty of Medicine: Mitsuaki Isobe, Kenzo Hirao; Tokyo Metropolitan Hiroo Hospital: Harumizu Sakurada, Tsuyoshi Sakai, Hidetaka Okazaki, Akiko Tatsumoto; Toyama University Hospital: Hiroshi Inoue, Tomoki Kameyama; Tsuchiya General Hospital: Yasuhiko Hayashi, Yuji Muraoka; Yamaguchi University Hospital: Masunori Matsuzaki, Akihiko Shimizu; Yokohama City University Medical Center: Kazuo Kimura, Toshiaki Ebina.
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Kenji Ando, Takanori Ikeda, Yoshinori Kobayashi, Satoshi Shizuta.
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Asuka Saeki, Hiromi Yoshida, Yuko Yamamoto, Kumiko Kitagawa, Misato Yamauchi, Naoko Okamoto, Yumika Fujino, Izumi Miki, Yuki Sato, Yoko Fujiki, Rei Fujita, Miya Hanazawa, Miho Hayashikawa, Chikako Hibi, Takami Hiraoka, Sachiko Maeda, Saeko Minematsu, Ayu Motofusa, Satoko Nishida, Hitomi Sasae, Yayoi Sugimoto, Emi Takinami, Saori Tezuka, Ayumi Yamamoto, Mai Yoshimoto.

Investigators of the PRospective Evaluation of VENtricular Tachyarrhythmic events and Sudden Cardiac Death in patients with left ventricular dysfunction (PREVENT-SCD) study are listed in [Appendix 1](#Sec13){ref-type="sec"}.
